drugset / Trial / NCT02620163

Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment

NCT02620163

Phase 3 Completed 381 enrolled Yuhan Corporation
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate efficacy and safety of YH22162 versus telmisartan / amlodipine treatment in patients with hypertension inappropriately controlled on telmisartan/amlodipine treatment

Timeline

Start
2015-12
Primary completion
2016-12
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amlodipine Other / unclassified 5 mg
Subject Chlorthalidone Other / unclassified 12.5 mg
Subject Chlorthalidone Other / unclassified 25 mg
Comparator Telmisartan Other / unclassified 40 mg
Comparator Telmisartan Other / unclassified 80 mg